“We are pleased to have closed our non-dilutive financing transaction with HealthCare Royalty, which extends our cash runway into 2025,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “This financing will help us reach key clinical catalysts which we believe will validate the potential of our oral difelikefalin pipeline.”Posner continued, “We look forward to releasing topline efficacy and safety data from Part A of our KIND 1 atopic dermatitis trial in December. Our other two late-stage clinical programs for the treatment of pruritus associated with advanced chronic kidney disease and notalgia paresthetica are on track for key data readouts in 2024. We will continue to focus on maintaining a strong balance sheet and delivering on our commitments across our wholly owned pipeline.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARA:
- Cara Therapeutics Reports Third Quarter 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, November 13, 2023
- CARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cara Therapeutics announces up to $40M financing agreement with HCRx
- Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty